Manufacturing

Feliza Mirasol is the science editor for 

Articles

Lonza has made a deal with Acumen Pharmaceuticals to manufacture sabirnetug, a mAb that will soon be entering Phase II development for treating Alzheimer’s disease.

Lonza Set to Manufacture Acumen Pharmaceuticals’ mAb for Alzheimer’s Disease

ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection

ProBioGen and Mapp Biopharmaceutical Partner to Develop Antibody Against Marburg Virus Disease

Stijn H. S. Koshari is a principal investigator at Downstream Process Development, BioPharma R&D, GlaxoSmithKline, King of Prussia, Pennsylvania 19406.

Hong Zhang is an investigator at Downstream Process Development, BioPharma R&D, GlaxoSmithKline, King of Prussia, Pennsylvania 19406.

Antonio Ubiera is a senior director at Downstream Process Development, BioPharma R&D, GlaxoSmithKline, King of Prussia, Pennsylvania 19406.

Robert G. Luo is a scientific director, at Downstream Process Development, BioPharma R&D, GlaxoSmithKline, King of Prussia, Pennsylvania 19406.

The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.

Fouling Mechanisms of Filters During the Harvest Development of Monoclonal Antibody Therapeutics with Intensified Upstream Processes—Part 2

Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.

Samsung Biologics Partners with LegoChem Biosciences on ADCs 

Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.

Purolite and Repligen Launch New Affinity Resin

The authors present a methodology to assess the contribution of individual filters to overall capacity of the direct filtration train, and elucidate how capacity is affected by characteristics of the cell culture broth and process parameters, including for enhanced upstream processes such as those incorporating high cell density perfusion. 

Fouling Mechanisms of Filters During the Harvest Development of Monoclonal Antibody Therapeutics with Intensified Upstream Processes—Part 1

Abzena has launched its AbZelect platforms, designed for improving cell line development.

Abzena Launches New Cell Line Development Platforms

Ann Rossi Bilodeau, PhD, is senior bioprocess applications scientist at Corning Life Sciences.

Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.

The Pros and Cons of Adherent Versus Suspension Cell Culture

Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.

Lonza Launches New Cell Line for Higher Potency Antibody Development

As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.

Manufacturing, Monoclonal Antibodies